Industry Payments and Prescribing of Brand-Name Multiple Sclerosis Medications in Medicare

Neurology 2026

View at publisher
Authors: A. M. Patel, Aaron S. Kesselheim, Benjamin N. Rome
DOI: 10.1212/wnl.0000000000214834
Cited by: 1
References: 10

Abstract

OBJECTIVES: Industry payments to clinicians influence prescribing, limiting use of lower-cost generics, and leading to nonadherence. This study of prescribing for multiple sclerosis examined whether payments from brand-name drug manufacturers were associated with prescribing of brand-name glatiramer and dimethyl fumarate after generics became available. METHODS: This cross-sectional study used 2021-2022 Open Payments data and 2022-2023 Medicare Part D prescription data. Payments from Teva (glatiramer) and Biogen (dimethyl fumarate) were categorized as none,

Fields of Study & Subjects

Healthcare Policy and Management Pharmaceutical Economics and Policy Pharmaceutical industry and healthcare

Publication details

Journal / source
Neurology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Volume
106
Issue
8
Pages
e214834–e214834
Publication date
6 April 2026
Language
EN